Liquid-based cytology as a tool for the performance of uCyt+™ and Urovysion® Multicolour-FISH in the detection of urothelial carcinoma

Cytopathology

Volumn 14, Issue 6, 2003, Pages 338-342

  Mian, C ^a   Lodde, M ^a   Comploj, E ^a   Negri, G ^a   Egarter Vigl, E ^a   Lusuardi, L ^a   Palermo, S ^a   Marberger, M ^b   Pycha, A ^a  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Liquid based cytology; Multicolour FISH; uCyt+; Urothelial cancer

Indexed keywords

EOSIN; HEMATOXYLIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 19A211; MONOCLONAL ANTIBODY LDQ10; MONOCLONAL ANTIBODY M344; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASPIRATION CYTOLOGY; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTODIAGNOSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEMATOXYLIN EOSIN STAINING; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; MOLECULAR PROBE; PAPANICOLAOU TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STAINING; UROGENITAL TRACT TUMOR; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYTODIAGNOSIS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0347504939     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0956-5507.2003.00094.x     Document Type: Article

References (17)

1. Nasuti JF, Tam D, Gupta PK. Diagnostic value of liquid-based (ThinPrep) preparations in non-gynecologic cases. Diagn Cytopathol 2001;24:137-41.
2. Linder J. Recent advances in thin-layer cytology. Diagn Cytopathol 1998;18:24-32.
3. Wiener HG, Mian Ch, Haitel A et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998;159:1876-80.
4. Chopin DK, Laurent JC. Monoclonal antibodies in bladder cancer cytology. World J Urol 1991;9:75-78.
5. Fradet Y, Cordon-Cardo C. Critical appraisal of tumor markers in bladder cancer. Semin Urol 1993;11:145-53.
6. Soloway MS, Briggman JV, Carpinito GA et al. Use of a new marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156: 363-7.
7. Skacel M, Pettay JD, Tsiftsakis EK et al. Validation of a multicolour interphase fluorescence in situ hybridisation assay for detection of transitional cell carcinoma on fresh and archivial thinlayer, liquid-based cytology slides. Anal Quant Cytol Histol 2001;23:381-7.
8. Fradet Y, Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt™. Canad J Urol 1997;4:400-5.
9. Mian C, Pycha A, Wiener H et al. ImmunoCyt™: a new tool in for detecting transitional cell cancer of the urinary tract. J Urol 1999;161:1486-9.
10. Olsson H, Zackrisson B. ImmunoCyt™: a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 2001;35:280-2.
11. Lodde M, Mian C, Wiener H et al. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt™: a preliminary report. Urology 2001;58:362-6.
12. Halling KC, King W, Sokolova IA et al. A comparison of cytology and fluorescence in situ hybridisation for the detection of urothelial carcinoma. J Urol 2000;164: 1768-75.
13. Bubendorf L, Grilli B, Sauter G et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001; 116:79-86.
14. Sobin LH, Wittekind Ch. UICC TNM Classification of Malignant Tumours, 6th edn. New York, Chichester, Weinheim, Brisbane, Singapore, Toronto: Wiley-Liss; 2002: 199 pp.
15. Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. Acta Cytol 1985; 29:810-6.
16. Vriesma JLJ, Atsma LAL, Kiemeney WP, Peelen WP, Witijes JA, Schalken JA. Diagnostic efficacy of the Immunocyt test to detect superficial bladder cancer recurrence. Urology 2001;58:367-71.
17. Sarosdy MF, Schellhamer P, Bokinsky G et al. Clinical evaluation of a multitarget fluorescent in situ hybridization assay for detection of bladder cancer. J Urology 2002; 168:1950-4.